Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Resistance to PRMT5-targeted therapy in mantle cell lymphoma
PubMed Full text in PMC Similar studies
Resistance to PRMT5 Inhibitor Targeted Therapy in MCL
Resistance to PRMT5 Inhibitor Targeted Therapy in MCL [WES]
Resistance to PRMT5 Inhibitor Targeted Therapy in MCL [RNA-seq]
PubMed Full text in PMC Similar studies Analyze with GEO2R
FOXO1 dependent transcription network is a targetable vulnerability of Mantle Cell Lymphomas
FOXO1 dependent transcription network is a targetable vulnerability of Mantle Cell Lymphomas [RNA-Seq]
PubMed Full text in PMC Similar studies Analyze with GEO2RSRA Run Selector
FOXO1 dependent transcription network is a targetable vulnerability of Mantle Cell Lymphomas [ChIP-Seq]
PubMed Full text in PMC Similar studies SRA Run Selector
PRMT5 inhibition in MCL
Expression data from renal cancer patient-derived xenograft tumor treated with temsirolimus or vehicle
DNA methylation data from renal cancer patient-derived xenograft tumor treated with temsirolimus or vehicle
A novel target of EZH1/2 for treatment of mantle cell lymphoma
Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma
Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma [ATAC-seq]
Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma [array]
Synergistic activity of BET protein antagonist-based combinations in Mantle Cell Lymphoma cells sensitive or resistant to ibrutinib
Next generation sequencing facilitates analysis of the role of PRMT5 in diffuse large B-cell lymphoma (DLBCL)
PRMT5 Interacts with the BCL6 Oncoprotein and is Required for Germinal Center Formation and Lymphoma Cell Survival
SAM Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance
PubMed Similar studies Analyze with GEO2RSRA Run Selector
Ro, GSK-591 and combination treatment in Z-138 cells
HyperTRIBE uncovers MSI2 RNA binding activity and the effect of Ro, GSK-591 and combination in Z-138 cells
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on